Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd (SUNPHARMA) last traded at ₹1,913, a market capitalisation of ₹4,59,017 crore, on a P/E of 36.4. Over the past 52 weeks the stock has ranged between ₹1,547 and ₹2,048. Sun Pharmaceutical Industries Ltd last reported results for the quarter ended Jun 2026, with sales of ₹15,300 crore and net profit of ₹2,901 crore. The next scheduled event is an analyst meet on 1 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
Sun Pharmaceutical Industries Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Sun Pharmaceutical Industries Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹15,300 cr, up 10.5% from ₹13,851 cr a year earlier. Net profit was ₹2,901 cr, up 26.5% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 |
| Expenses | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 | 10,882 |
| Operating profit | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 |
| OPM % | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% |
| Other income | 354 | 149 | 251 | -354 | 470 | 89 | 458 | 520 |
| Interest | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 |
| Depreciation | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 |
| Profit before tax | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 |
| Tax % | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% |
| Net profit | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 |
| EPS (₹) | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 | 14.04 | 11.31 | 12.06 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Sun Pharmaceutical Industries Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 33,498 | 38,654 | 43,886 | 48,497 | 52,578 | 58,462 | 59,911 |
| Operating profit | 8,470 | 10,258 | 11,650 | 13,018 | 15,114 | 16,501 | 17,847 |
| OPM % | 25% | 27% | 27% | 27% | 29% | 28% | 30% |
| Net profit | 2,272 | 3,389 | 8,513 | 9,610 | 10,965 | 11,509 | 12,117 |
| EPS (₹) | 12.10 | 13.64 | 35.32 | 39.91 | 45.55 | 47.84 | 50.41 |
TTM is the trailing twelve months to the most recent quarter.
Sun Pharmaceutical Industries Ltd growth and returns
- 10 Years
- 7%
- 5 Years
- 12%
- 3 Years
- 10%
- TTM
- 11%
- 10 Years
- 10%
- 5 Years
- 17%
- 3 Years
- 13%
- TTM
- 10%
- 10 Years
- 10%
- 5 Years
- 20%
- 3 Years
- 20%
- 1 Year
- 15%
- 10 Years
- 14%
- 5 Years
- 16%
- 3 Years
- 16%
- Last Year
- 16%
Sun Pharmaceutical Industries Ltd shareholding pattern
Promoters held 54.48% at Jun 2026, broadly unchanged since Jun 2025. FIIs 14.54% and DIIs 22.06%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% | 54.48% |
| FIIs | 18.01% | 18.04% | 17.96% | 17.26% | 16.55% | 16.12% | 15.94% | 14.54% |
| DIIs | 18.48% | 18.43% | 18.58% | 19.38% | 20.12% | 20.72% | 21.00% | 22.06% |
| Government | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% | 0.11% |
| Public | 8.89% | 8.92% | 8.86% | 8.76% | 8.72% | 8.57% | 8.48% | 8.81% |
| No. of shareholders | 6,57,317 | 6,89,623 | 7,04,983 | 7,23,770 | 7,43,877 | 7,10,900 | 6,90,957 | 7,10,246 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Sun Pharmaceutical Industries Ltd events
The next scheduled event is an analyst meet on 1 Sept 2026.
- Analyst meetAshwamedh – Elara India Dialogue 2026
- OtherShareholder approval for reclassification of certain promoter group members to public category
See the full results calendar for every Indian company reporting in the next 30 days.
Sun Pharmaceutical Industries Ltd corporate filings
- Notice of Postal Ballot/E-votingAGM/EGMlow impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited has issued a notice for a postal ballot to seek…
Read the full analysis - Intimation of Schedule of Analyst/Institutional Investor MeetingCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd has issued an intimation regarding a scheduled meeting…
Read the full analysis - Update on Lipitor Antitrust LitigationCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries has issued a status update regarding the ongoing Lipitor…
Read the full analysis - Receipt of No-objection letters from the Stock Exchanges for Reclassification of Promoter GroupCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd has received no-objection letters from stock exchanges…
Read the full analysis - Q1FY27 Earnings Call TranscriptCompany Updatehigh impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited reported Q1 FY27 consolidated sales of INR 15,184…
Read the full analysis - Intimation of Schedule of Analyst/Institutional Investor MeetingCompany Updatelow impact
Cruxal's analysis: Sun Pharmaceutical Industries Ltd has issued an intimation regarding a scheduled meeting…
Read the full analysis - Update on Credit RatingCompany Updatemedium impact
Cruxal's analysis: Sun Pharmaceutical Industries Limited has announced that CRISIL Ratings Limited has…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Sun Pharmaceutical Industries Ltd
Cruxal reads every Sun Pharmaceutical Industries Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.